|
🐜
|
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
16 auth.
D. Marin,
Amr Ibrahim,
C. Lucas,
G. Gerrard,
Lihui Wang,
Richard Szydlo,
R. Clark,
J. Apperley,
D. Milojkovic,
M. Bua,
...
J. Pavlů,
Christos Paliompeis,
A. Reid,
K. Rezvani,
J. Goldman,
L. Foroni
|
8 |
2012 |
8
🐜
|
|
🐜
|
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
15 auth.
D. Marin,
D. Milojkovic,
E. Olavarría,
J. Khorashad,
H. de Lavallade,
A. Reid,
L. Foroni,
K. Rezvani,
M. Bua,
F. Dazzi,
...
J. Pavlů,
M. Klammer,
J. Kaeda,
J. Goldman,
J. Apperley
|
8 |
2008 |
8
🐜
|
|
🐜
|
Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia
16 auth.
K. Stringaris,
T. Sekine,
A. Khoder,
A. Alsuliman,
Bonnie Razzaghi,
Ruhena Sargeant,
J. Pavlů,
Gill Brisley,
H. de Lavallade,
Anushruti Sarvaria,
...
D. Marin,
S. Mielke,
J. Apperley,
E. Shpall,
J. Barrett,
K. Rezvani
|
7 |
2014 |
7
🐜
|
|
🐢
|
Treatment and management of graft-versus-host disease: improving response and survival
C. Garnett,
J. Apperley,
J. Pavlů
|
7 |
2013 |
7
🐢
|
|
🐜
|
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
17 auth.
A. Chaidos,
Scott J. Patterson,
Richard Szydlo,
M. Chaudhry,
F. Dazzi,
E. Kanfer,
Donald McDonald,
D. Marin,
D. Milojkovic,
J. Pavlů,
...
John Davis,
A. Rahemtulla,
K. Rezvani,
J. Goldman,
I. Roberts,
J. Apperley,
A. Karadimitris
|
7 |
2012 |
7
🐜
|
|
🐜
|
Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host
20 auth.
H. de Lavallade,
P. Garland,
T. Sekine,
K. Hoschler,
D. Marin,
K. Stringaris,
E. Loucaides,
K. Howe,
Richard Szydlo,
E. Kanfer,
...
D. Macdonald,
P. Kelleher,
N. Cooper,
A. Khoder,
I. Gabriel,
D. Milojkovic,
J. Pavlů,
J. Goldman,
J. Apperley,
K. Rezvani
|
7 |
2011 |
7
🐜
|
|
🦁
|
Three decades of transplantation for chronic myeloid leukemia: what have we learned?
J. Pavlů,
Richard Szydlo,
J. Goldman,
J. Apperley
|
6 |
2011 |
6
🦁
|
|
🐜
|
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia
27 auth.
C. Craddock,
Aimee E Jackson,
J. Loke,
S. Siddique,
A. Hodgkinson,
J. Mason,
Georgia Andrew,
S. Nagra,
R. Malladi,
A. Peniket,
M. Gilleece,
R. Salim,
E. Tholouli,
V. Potter,
C. Crawley,
...
K. Wheatley,
R. Protheroe,
P. Vyas,
A. Hunter,
A. Parker,
K. WIlson,
J. Pavlů,
J. Byrne,
R. Dillon,
N. Khan,
N. McCarthy,
S. Freeman
|
6 |
2020 |
6
🐜
|
|
🐜
|
The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
58 auth.
A. Rio-Machin,
T. Vulliamy,
N. Hug,
A. Walne,
K. Tawana,
S. Cardoso,
A. Ellison,
N. Pontikos,
Jun Wang,
H. Tummala,
Ahad Al Seraihi,
Jenna Alnajar,
Findlay Bewicke-Copley,
H. Armes,
Michael Barnett,
...
A. Bloor,
Csaba Bödör,
David T. Bowen,
P. Fenaux,
Andrew Green,
Andrew R. Hallahan,
Henrik Hjorth-Hansen,
Upal Hossain,
S. Killick,
Sarah Lawson,
Mark Layton,
Alison M. Male,
Judith Marsh,
Priyanka Mehta,
R. Mous,
J. Nomdedéu,
Carolyn Owen,
J. Pavlů,
Elspeth M. Payne,
R. Protheroe,
C. Preudhomme,
N. Pujol-Moix,
Aline Renneville,
Nigel Russell,
A. Saggar,
G. Sciuccati,
D. Taussig,
C. Toze,
A. Uyttebroeck,
P. Vandenberghe,
B. Schlegelberger,
T. Ripperger,
D. Steinemann,
John Wu,
J. Mason,
Paula Page,
S. Akiki,
K. Reay,
J. Cavenagh,
V. Plagnol,
J. Cáceres,
J. Fitzgibbon,
I. Dokal
|
6 |
2020 |
6
🐜
|
|
🦁
|
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.
14 auth.
J. Pavlů,
A. Kew,
Beatrice Taylor-Roberts,
H. Auner,
D. Marin,
E. Olavarría,
E. Kanfer,
D. Macdonald,
D. Milojkovic,
A. Rahemtulla,
...
K. Rezvani,
J. Goldman,
J. Apperley,
Richard Szydlo
|
6 |
2010 |
6
🦁
|
